<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682367</url>
  </required_header>
  <id_info>
    <org_study_id>1166778</org_study_id>
    <nct_id>NCT03682367</nct_id>
  </id_info>
  <brief_title>Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery</brief_title>
  <official_title>Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing head and neck cancer surgery often have a lot of pain after surgery,&#xD;
      which can lead to a need for a lot of narcotic pain medication. These medications can have&#xD;
      many side effects that can make recovery more difficult including nausea, vomiting,&#xD;
      dizziness, being overly sleepy, itchiness, inability to urinate, confusion, inability to have&#xD;
      a bowel movement, longer time before being able to start walking. These side effects can make&#xD;
      the hospital stay longer. The use of gabapentin, which is a non narcotic pain medication that&#xD;
      focuses on nerve pain, has been used in smaller head and neck surgeries including removal of&#xD;
      tonsils, sinus surgery, thyroid surgery. Studies in patients needing orthopedic or OB/Gyn&#xD;
      surgery have shown improved pain control with gabapentin. Potential benefits to future&#xD;
      patients include improved pain control, less narcotic associated side effects and faster&#xD;
      functional recovery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing head and neck cancer surgery frequently experience significant post&#xD;
      surgical pain, which often necessitates the use of narcotic pain medication. However, opioids&#xD;
      can have multiple side effects that can complicate the head and neck cancer surgery patients&#xD;
      postoperative care including nausea, vomiting, dizziness, sedation, pruritis, urinary&#xD;
      retention, delirium, constipation, and time to ambulation. This, in turn, may affect patient&#xD;
      length and cost of hospital stay. Consequently, a multimodal approach to analgesia is often&#xD;
      employed with a focus on use of scheduled acetaminophen +/- NSAIDs supplemented with&#xD;
      narcotics.&#xD;
&#xD;
      The use of gabapentin in the head and neck surgery literature has largely been limited to&#xD;
      outpatient surgeries, including tonsillectomy in children and adults, functional endoscopic&#xD;
      sinus surgery, and thyroidectomy. Indeed, a recent systematic review examined RCT comparing&#xD;
      multimodal analgesia with gabapentin to analgesia without gabapentin in the otolaryngology&#xD;
      literature. The majority of these studies employed preoperative dosing only, with only 1&#xD;
      study providing a single postoperative dose as well. The control group pain regimen among&#xD;
      these studies did vary and included a combination of acetaminophen, NSAIDs, dexmedetomidine,&#xD;
      or clonidine supplemented with opioids. The studies focused on the impact of gabapentin on&#xD;
      acute postoperative pain determined by subjective measurement of reduction in visual analog&#xD;
      pain scale. Of note, these patients were not hospitalized for longer than 24 hours. The&#xD;
      thyroid and sinus studies consistently demonstrated improved pain control with use of&#xD;
      gabapentin compared to control. The data was slightly more variable across the tonsillectomy&#xD;
      studies. Moreover, 7 studies also measured the need for breakthrough pain medication and&#xD;
      supplemental analgesia; each of these studies demonstrated significantly less supplemental&#xD;
      analgesia consumption in the gabapentin group.&#xD;
&#xD;
      The only study examining the utility of gabapentin in pain management in head and neck cancer&#xD;
      patients (glossectomy with anterolateral thigh free flap) examined the utility of a single&#xD;
      preoperative dose. The authors concluded that this led to a significant reduction in&#xD;
      subjective postoperative pain scores, morphine requirement, and nausea and vomiting compared&#xD;
      to controls. This study did not employ postoperative gabapentin.&#xD;
&#xD;
      Furthermore, a recent meta analysis (133 RCT) examining literature across multiple surgical&#xD;
      specialties pertaining to the efficacy of perioperative gabapentin supplementation vs&#xD;
      placebo. The meta analysis indicated both the efficacy of gabapentin supplementation in&#xD;
      decreasing opioid requirement (measured via morphine equivalent units) in the experimental&#xD;
      group during the first 24 hours (P&lt;0.001), as well as a good safety profile across a wide&#xD;
      range of loading and maintenance doses (200 to 1200 mg) of gabapentin. The significant&#xD;
      reduction in opioid requirement was independent of surgery type. Moreover, the gabapentin&#xD;
      group demonstrated a significant decrease in VAS postoperative pain scores, nausea, vomiting&#xD;
      and itching; however, sedation scores were increased. Only 8 of these 133 RCT examined the&#xD;
      effect of gabapentin outside the immediate 24 hour period, and all 8 trials demonstrated&#xD;
      improvement in chronic pain scores at 3 months post-operatively. Finally, patient&#xD;
      satisfaction scores and preoperative anxiety were also significantly improved with the use of&#xD;
      gabapentin compared to controls.&#xD;
&#xD;
      Here, the investigators propose, for the first time, a superiority double blind randomized&#xD;
      controlled placebo trial examining the effect of perioperative supplementation with&#xD;
      gabapentin in head and neck cancer patients undergoing surgery. The primary purpose of this&#xD;
      study is to determine the difference in morphine equivalent units between the experimental&#xD;
      (i.e. perioperative gabapentin) and control group (i.e. no perioperative gabapentin). The&#xD;
      secondary purpose of this study is to determine differences across the two groups in relation&#xD;
      to the following: visual analog pain scores, cost and length of stay, medication side&#xD;
      effects, and incidence of postoperative complications. Of note, in order to maximize&#xD;
      reliability of the visual analog scale (VAS), prior studies have employed the Jadad scoring&#xD;
      system, which the investigators will also implement in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor Recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Actual">April 6, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>All staff involved including nursing, surgeons, pain management, participants and PI will be blinded. Unmasked personnel only include research pharmacy staff.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Average Morphine Equivalent Units</measure>
    <time_frame>Perioperative.</time_frame>
    <description>Determine the difference in average morphine equivalent units between experimental and control group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Morphine Equivalent Units</measure>
    <time_frame>1 week post-operation.</time_frame>
    <description>Determine the difference in average morphine equivalent units between experimental and control group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Morphine Equivalent Units</measure>
    <time_frame>30 days post-operation.</time_frame>
    <description>Determine the difference in average morphine equivalent units between experimental and control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score (10 Point VAS)</measure>
    <time_frame>Perioperative, 1 week post-operation, 1 week post-discharge, and 30 days post-operation.</time_frame>
    <description>Determine average change of inpatient Pain Score Visual Analog Scale (VAS) on a standardized 1 (no pain) to 10 (highest level of pain) scale between experimental and control groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Complications</measure>
    <time_frame>30 days post-operation.</time_frame>
    <description>Incidence of postoperative complications between experimental and control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotics-related Complications</measure>
    <time_frame>30 days post-operation.</time_frame>
    <description>Incidence of narcotics-related complications between experimental and control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inpatient Length of Stay</measure>
    <time_frame>1 week post-operation.</time_frame>
    <description>Determine the difference of average inpatient length of stay between experimental and control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inpatient Cost</measure>
    <time_frame>1 week post-operation.</time_frame>
    <description>Determine the difference of average inpatient cost between experimental and control group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Cancer of Head and Neck</condition>
  <condition>Narcotic Use</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Use of Gabapentin peri- and post-operatively.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Neurontin</other_name>
    <other_name>Gralise</other_name>
    <other_name>Horizant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Concentrate</intervention_name>
    <description>Use of sugar-free Placebo peri- and post-operatively.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing major head and neck surgery with concomitant free flap&#xD;
             reconstruction surgery at UCDMC (oncology and non-oncologic): There will be two&#xD;
             groups. Group 1 will include reconstruction with fibula free flap only. Group 2 will&#xD;
             include any other free flap reconstruction, including scapular free flap, radial&#xD;
             forearm free flap, anterolateral thigh free flap, anteromedial thigh free flap, and&#xD;
             latissimus dorsi free flap.&#xD;
&#xD;
          -  Patients na√Øve to gabapentin&#xD;
&#xD;
          -  Adult patients &gt;18 years of age and able to consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are already taking scheduled gabapentin&#xD;
&#xD;
          -  Patients allergic to gabapentin&#xD;
&#xD;
          -  Chronic opioid use not from active head and neck cancer&#xD;
&#xD;
          -  Illicit drug use (per report)&#xD;
&#xD;
          -  Patients with known renal compromise, such that Creatinine clearance is &lt; 30&#xD;
&#xD;
          -  Patient with known hepatic insufficiency or cirrhosis&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Individuals less than 18 years old&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Bewley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <results_first_submitted>June 3, 2021</results_first_submitted>
  <results_first_submitted_qc>July 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 9, 2021</results_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gabapentin</keyword>
  <keyword>Narcotic</keyword>
  <keyword>Cancer</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03682367/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03682367/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.&#xD;
Placebo - Concentrate: Use of sugar-free Placebo peri- and post-operatively.</description>
        </group>
        <group group_id="P2">
          <title>Intervention</title>
          <description>Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.&#xD;
Gabapentin: Use of Gabapentin peri- and post-operatively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2">Withdrawn due to non-compliance</participants>
                <participants group_id="P2" count="0">Patients withdrawn due to confounding neuropathic pain or exited early from study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Closed Study Early</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.&#xD;
Placebo - Concentrate: Use of sugar-free Placebo peri- and post-operatively.</description>
        </group>
        <group group_id="B2">
          <title>Intervention</title>
          <description>Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.&#xD;
Gabapentin: Use of Gabapentin peri- and post-operatively.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Morphine Equivalent Units</title>
        <description>Determine the difference in average morphine equivalent units between experimental and control group.</description>
        <time_frame>Perioperative.</time_frame>
        <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.&#xD;
Placebo - Concentrate: Use of sugar-free Placebo peri- and post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.&#xD;
Gabapentin: Use of Gabapentin peri- and post-operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Morphine Equivalent Units</title>
          <description>Determine the difference in average morphine equivalent units between experimental and control group.</description>
          <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Morphine Equivalent Units</title>
        <description>Determine the difference in average morphine equivalent units between experimental and control group.</description>
        <time_frame>1 week post-operation.</time_frame>
        <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.&#xD;
Placebo - Concentrate: Use of sugar-free Placebo peri- and post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.&#xD;
Gabapentin: Use of Gabapentin peri- and post-operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Morphine Equivalent Units</title>
          <description>Determine the difference in average morphine equivalent units between experimental and control group.</description>
          <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Morphine Equivalent Units</title>
        <description>Determine the difference in average morphine equivalent units between experimental and control group.</description>
        <time_frame>30 days post-operation.</time_frame>
        <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.&#xD;
Placebo - Concentrate: Use of sugar-free Placebo peri- and post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.&#xD;
Gabapentin: Use of Gabapentin peri- and post-operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Morphine Equivalent Units</title>
          <description>Determine the difference in average morphine equivalent units between experimental and control group.</description>
          <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score (10 Point VAS)</title>
        <description>Determine average change of inpatient Pain Score Visual Analog Scale (VAS) on a standardized 1 (no pain) to 10 (highest level of pain) scale between experimental and control groups.</description>
        <time_frame>Perioperative, 1 week post-operation, 1 week post-discharge, and 30 days post-operation.</time_frame>
        <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.&#xD;
Placebo - Concentrate: Use of sugar-free Placebo peri- and post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.&#xD;
Gabapentin: Use of Gabapentin peri- and post-operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score (10 Point VAS)</title>
          <description>Determine average change of inpatient Pain Score Visual Analog Scale (VAS) on a standardized 1 (no pain) to 10 (highest level of pain) scale between experimental and control groups.</description>
          <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Complications</title>
        <description>Incidence of postoperative complications between experimental and control group.</description>
        <time_frame>30 days post-operation.</time_frame>
        <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.&#xD;
Placebo - Concentrate: Use of sugar-free Placebo peri- and post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.&#xD;
Gabapentin: Use of Gabapentin peri- and post-operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Complications</title>
          <description>Incidence of postoperative complications between experimental and control group.</description>
          <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Narcotics-related Complications</title>
        <description>Incidence of narcotics-related complications between experimental and control group.</description>
        <time_frame>30 days post-operation.</time_frame>
        <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.&#xD;
Placebo - Concentrate: Use of sugar-free Placebo peri- and post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.&#xD;
Gabapentin: Use of Gabapentin peri- and post-operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Narcotics-related Complications</title>
          <description>Incidence of narcotics-related complications between experimental and control group.</description>
          <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inpatient Length of Stay</title>
        <description>Determine the difference of average inpatient length of stay between experimental and control group.</description>
        <time_frame>1 week post-operation.</time_frame>
        <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.&#xD;
Placebo - Concentrate: Use of sugar-free Placebo peri- and post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.&#xD;
Gabapentin: Use of Gabapentin peri- and post-operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Inpatient Length of Stay</title>
          <description>Determine the difference of average inpatient length of stay between experimental and control group.</description>
          <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inpatient Cost</title>
        <description>Determine the difference of average inpatient cost between experimental and control group.</description>
        <time_frame>1 week post-operation.</time_frame>
        <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.&#xD;
Placebo - Concentrate: Use of sugar-free Placebo peri- and post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.&#xD;
Gabapentin: Use of Gabapentin peri- and post-operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Inpatient Cost</title>
          <description>Determine the difference of average inpatient cost between experimental and control group.</description>
          <population>Due to safety concerns and patient non-compliance, the data was unreliable and uninterpretable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>Any known untoward event of any severity that occurs subsequent to the AE reporting period that the Investigator assesses as at least possibly related to the study therapy (i.e., the relationship cannot be ruled out) should also be reported as an AE.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.&#xD;
Placebo - Concentrate: Use of sugar-free Placebo peri- and post-operatively.</description>
        </group>
        <group group_id="E2">
          <title>Intervention</title>
          <description>Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.&#xD;
Gabapentin: Use of Gabapentin peri- and post-operatively.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Constipation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early study termination was decided after several technical issues regarding study logistics and patient non-compliance lead to unreliable and uninterpretable data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Arnaud Bewley</name_or_title>
      <organization>UC Davis Health</organization>
      <phone>9167342704</phone>
      <email>abewley@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

